Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Homeobox protein Hox-A3 (HOXA3)
- Target
- HOXA3
- Molecular classification
- Transcription factor, Homeobox gene family, Sequence-specific DNA-binding protein
01
Overview
Homeobox protein Hox-A3 (HOXA3) is a DNA-binding, sequence-specific transcription factor that is a member of the homeobox gene family, located in the A cluster on human chromosome 7. It is crucial for embryonic development, where it orchestrates the spatial and temporal regulation of genes required for the morphogenesis of key organs derived from the pharyngeal region, such as the thymus, parathyroid, and thyroid. In the nervous system, HOXA3 is involved in specifying neuronal identity and segmenting the hindbrain. Its expression is tightly controlled and, in adults, can be re-induced during wound healing to promote tissue remodeling and angiogenesis. Pathogenic variants or knockout of HOXA3 lead to severe developmental defects, and its dysregulation has been associated with certain cancers and congenital organ malformations.
- Other names
- Homeobox A3HOXA3HOX1EHomeobox protein Hox-1EHOX1Hox-1.5-like proteinhomeo box 1Ehomeo box A3HXA3_HUMAN (UniProt entry)
02
Mechanism of action
No drugs with an established mechanism of action targeting HOXA3 are known, as it is not a conventional drug target.
03
Biological functions
Regulation of gene expressionEmbryonic morphogenesis and organ development (e.g., thymus, parathyroid, thyroid formation)Differentiation and patterning (anterior–posterior axis, hindbrain segmentation)Tissue repair and angiogenesis (in adult wound healing)Specification of neuronal progenitors in CNS development
04
Disease associations
Congenital gland development disorders (linked with defective thymus and parathyroid development, overlap with DiGeorge syndrome phenotypes)Cancer (notably, familial thyroid dyshormonogenesis, penile cancer; roles in other cancers are being investigated)Other developmental defects (e.g., abnormal carotid artery, carotid body absence in animal models)
05
Safety considerations
No clinical data on safety concerns for therapeutically targeting HOXA3 exist, as targeting transcription factors for therapy—especially those with broad developmental roles—poses significant challenges due to potential widespread and critical effects on organogenesis and tissue differentiation.
06
Biomarkers
Potential research biomarker: Expression of HOXA3 and its transcriptional signature could be explored as a developmental biomarker or in certain cancers, but it is not an established clinical biomarker
Beyond the preview
Go deeper on Homeobox protein Hox-A3 (HOXA3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Homeobox protein Hox-A3 (HOXA3).